ASCO Highlights Barriers to Cancer Care and New Treatments Amid Memorable Pancreatic Cancer Study Ovation
The annual ASCO meeting featured extensive discussion of the obstacles patients face in accessing cancer care and showcased a range of emerging therapies.
STAT compiled a quick‑take newsletter that distills the most notable moments from the world’s largest oncology conference.
A standout session was the plenary on the daraxonrasib pancreatic cancer study, which earned a prolonged standing ovation as presenter Brian Wolpin described it as two decades of work condensed into a brief presentation.
Overall, attendees described the gathering as a memorable showcase of both scientific progress and the ongoing challenges in the cancer treatment landscape.
This writeup was produced by pharmadog from original reporting by STAT.
Original headline: “STAT+: At ASCO, talk of barriers to cancer care, new treatments, and other big takeaways”
read at STAT ↗
comments(0)
5-min edit window · permanent after that